| DC72891 |
CWI1-2 hydrochloride
Featured
|
CWI1-2 hydrochloride is an inhibitor of IGF2BP2 that binds IGF2BP2 and inhibits its interaction with m6A-modified target transcripts, induces apoptosis and differentiation, and shows promising anti-leukemic effects. |
|
| DC72892 |
MEHP
Featured
|
MEHP (Phthalic acid mono-2-ethylexyl ester) is a competitive inhibitor of CYP2C9 with IC50 of 6.37 μM. |
|
| DC72893 |
TP-1454
Featured
|
TP-1454 is an activator of PKM2 with AC50 of 10 Nm in biochemical assays.TP-1454 modulates tumor-immune responses by destabilizing T-regulatory cells. |
.png)
|
| DC65349 |
ALC-0315 analgous-3
Featured
|
ALC-0315 analgous-3 is an butanolamine ionizable lipid with both ester bonds located adjacent to C8 relative to the amine head. The introduction of ester linkages can improve the clearance of the lipid in the liver. This compound is analgous to ALC-0315. |
|
| DC60468 |
MS78
Featured
|
MS78 is the first p53Y220C AceTAC which recruits histone acetyltransferase p300/CBP to acetylate the p53Y220C mutant with little toxicity in cancer cells with wild-type p53. |
|
| DC60469 |
AZD4747
Featured
|
AZD4747 is a highly potent and selective inhibitor of KRASG12C with IC50 of 15 nM. AZD4747 also shows an anticipated low clearance and high oral bioavailability profile in humans. |
|
| DC65381 |
PDS-0330
Featured
|
PDS-0330 is a specific and potent Claudin-1 inhibitor. PDS-0330 interferes with claudin-1/Src association and inhibits colorectal cancer (CRC) progression and metastasis. |
|
| DC65382 |
CWI1-2
Featured
|
CWI1-2 is an IGF2BP2 inhibitor that binds IGF2BP2 and inhibits its interaction with m6A-modified target transcripts, induces apoptosis and differentiation, and shows promising anti-leukemic effects. |
|
| DC65412 |
Acuitas Lipid III-2
Featured
|
Acuitas Lipid III-2 is an ionizable amine lipid with two identical ester tails adjacent to C6 position relative to amine from patent:WO2017075531A1 with the similar activity as ALC-0315. The head of lipid is propanolamine which can effectively encapsulate mRNA used in gene therapies which depends on the availability of a safe and efficient delivery vehicle. |
|
| DC65434 |
SM102 Analog 1
Featured
|
An analog of SM-102. The ethanolamine amino lipid head enhances encapsulation of mRNA. The lipid has primary esters at C7 position relative to the amine nitrogen. The primary lipid tail has 8 carbon tail. The lipid can be used for mRNA-based therapies which depends on the availability of a safe and efficient delivery vehicle. |
|
| DC65436 |
AkaLumine hydrochloride
Featured
|
AkaLumine hydrochloride is a luciferin analogue, with a Km of 2.06 μM for recombinant Fluc protein. |
|
| DC65437 |
LNP Lipid-2
Featured
|
LNP Lipid-2 is a lipid product can be used to deliver agents. |
|
| DC65438 |
SM-102 Analog 2(Compound 8-8)
Featured
|
SM-102 Analog 2(Compound 8-8) is a lipid compound. SM-102 Analog 2(Compound 8-8) is involved in the synthesis of lipid nanoparticles compositions. SM-102 Analog 2(Compound 8-8) has potential applications in the transportation of biologically active substances. |
|
| DC65439 |
LNP Lipid-6
Featured
|
LNP Lipid-6 (Compound Lipid 5) is an ionizable lipid (amino lipid). LNP Lipid-6 can be used to prepare lipid nanoparticles (LNP). |
|
| DC86805 |
Lipid 23
Featured
|
Lipid 23 is an ionizable cationic amino lipid (pKa = 5.7) that has been used with other lipids in the formulation of lipid nanoparticles (LNPs). Intravenous administration of LNPs containing lipid 23 and encapsulating an mRNA reporter accumulate specifically in the mouse liver. |
|
| DC60473 |
SMD-3040
Featured
|
SMD-3040 is a potent and selective SMARCA2 degrader with DC50 of 12 nM and demonstrates an excellent degradation selectivity for SMARCA2 over SMARCA4. SMD-3040 achieves strong tumor growth inhibition in two SMARCA4-deficient xenograft models at well-tolerated dose schedules. |
|
| DC60479 |
AOH1996
Featured
|
AOH1996 is a proliferating cell nuclear antigen (PCNA) inhibitor. AOH1996 enhances PCNA and RPB1 interaction and interferes with TRC resolution and induces DNA double-stranded breaks in a transcription dependent manner. AOH1996 almost completely inhibits the growth of xenograft tumors without causing any discernible toxicity to experimental animals.AOH1996 has superior metabolic stability as compared to the AOH1160 parent molecule. |
|
| DC60477 |
Lipid Catechol
Featured
|
Lipid catechol is a lipid that contains an α-aminophosphonate group, two 14-carbon acyl chains, and a catechol ring that forms a covalent bond with boronic acid-containing compounds to form lipid prodrug nanoassemblies (LPNA).1 LPNAs composed of lipid catechol conjugated to phenylboronic acid-modified ciprofloxacin (CIP-PBA) inhibit the formation of, and disrupt preformed, S. aureus biofilms and eradicate staphylococci in a mouse model of peritoneal S. aureus infection. LPNAs composed of lipid catechol conjugated to bortezomib (BTZ) reduce tumor growth and increase survival in a 4T1 murine mammary carcinoma model. |
|
| DC60478 |
ALC-0366
Featured
|
ALC-0366 is an ionizable cationic lipid (pKa = 6.25) from Biontech,which is derived from ALC-0315. ALC0366 has been used as a key component of LNP to deliver BNT142, a lipid nanoparticle (LNP)-formulated RNA (RNA-LNP) encoding a T cell-engaging bispecific antibody that monovalently binds the T cell marker CD3 and bivalently binds claudin 6 (CLDN6), an oncofetal antigen that is absent from normal adult tissue but expressed on various solid tumors. |
|
| DC60481 |
SC9
Featured
|
SC9 is an uncompetitive inhibitor of WT dynamin-related protein 1 (Drp1) with IC50 of 270 nM. SC9 completely prevents the LPS-induced decline in cells with fused mitochondria. |
|
| DC89030 |
SM-102 IMPURITY 1
Featured
|
|
|
| DC65441 |
Recilisib
Featured
|
Recilisib (ON01210, EX-RAD) is a radioprotectant that activates the activity of AKT and PI3K in cells. It has been studied as prophylactic (use prior to radiation exposure) and therapeutic (after exposure to radiation) drug. |
|
| DC65442 |
WAY-119064
Featured
|
way-119064 is a highly potent GSK-3β inhibitor with an IC50 value of 80.5 nM. GSK-3β inhibitor 10 can be used for researching Alzheimer’s disease[1]. |
|
| DC65443 |
SC-1
Featured
|
SC-1 (1-(4-Chloro-3-(trifluoromethyl)phenyl)-3-(4-(4-cyanophenoxy)phenyl)urea, STAT3-IN-7), a Sorafenib analogue and potently inhibits the phosphorylation of STAT3, induces cell apoptosis through SHP-1 dependent STAT3 inactivation. |
|
| DC65444 |
Stafia-1
Featured
|
Stafia-1 is the first STAT5a inhibitor that inhibits STAT5a (IC50=22.2 μM, Ki=10.9 μM) with at least 9‐fold selectivity over STAT5b and higher selectivity against other STAT family members. |
|
| DC65446 |
ATR inhibitor 1
Featured
|
ATR inhibitor 1 is a ATR inhibitor extracted from patent WO2015187451A1, compound I-l, has a Ki value below 1 µΜ[1]. |
|
| DC65447 |
Uridine,5-chloro-2'-deoxy-
Featured
|
5-Chloro-2'-deoxyuridine, a thymine analog, is to study the potential of hypochlorous acid damage to DNA and DNA precursors. |
|
| DC65448 |
Dxd
Featured
|
Dxd is a potent DNA topoisomerase I inhibitor, with an IC50 of 0.31 μM, used as a conjugated drug of HER2-targeting ADC (DS-8201a). |
|
| DC65449 |
ATM Inhibitor-5
Featured
|
ATM Inhibitor-5 [formula (1)] is a potent inhibitor of serine/threonine protein kinase ATM (extracted from patent WO2022058351A1)[1]. |
|
| DC65451 |
Bisindolylmaleimide VIII (acetate)
Featured
|
Bisindolylmaleimide VIII acetate (Ro 31-7549 acetate) is a potent and selective protein kinase C (PKC) inhibitor with an IC50 of 158 nM for rat brain PKC. Bisindolylmaleimide VIII acetate has IC50s of 53, 195, 163, 213, and 175 nM for PKC-α, PKC-βI, PKC-βII, PKC-γ, PKC-ε, respectively[1]. Bisindolylmaleimide VIII acetate facilitates Fas-mediated apoptosis and inhibits T cell-mediated autoimmune diseases[2]. |
|
